STOCK TITAN

Wasatch Advisors holds 2.13M Journey Medical (NASDAQ: DERM) — 10% stake

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Journey Medical Corp ownership disclosure: Wasatch Advisors reports beneficial ownership of 2,133,370 shares, representing 10.0% of the common stock as reported 03/31/2026. The filing shows sole voting power for 1,979,366 shares and sole dispositive power for 2,133,370 shares.

Positive

  • None.

Negative

  • None.

Insights

Large passive holding disclosed by an institutional investor.

Wasatch Advisors reports a 10.0% stake in Journey Medical as of 03/31/2026. The position size is significant for an institutional holder and appears to be held with sole dispositive authority.

The disclosure is routine under Schedule 13G/A amendments; the filing documents the holder's current position and voting/dispositive powers but does not state intent or planned transactions.

Voting and dispositive powers indicate control over disposition decisions.

The filing lists 1,979,366 shares with sole voting power and 2,133,370 shares with sole dispositive power. That split shows Wasatch can direct sales and exercises voting influence on most of its economic interest.

No change-of-control language or intent is included; follow-up disclosures would be required for any active proposals or plans to trade.

Beneficial ownership 2,133,370 shares as of 03/31/2026
Percent of class 10.0% reported on Schedule 13G/A
Sole voting power 1,979,366 shares as stated in the filing
Sole dispositive power 2,133,370 shares as stated in the filing
Schedule 13G/A regulatory
"Amendment No. 2 to Schedule 13G/A reporting beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficial ownership financial
"Amount beneficially owned: 2,133,370 (b) Percent of class: 10.0 %"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 2,133,370"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Wasatch Advisors hold in Journey Medical (DERM)?

Wasatch Advisors reports beneficial ownership of 2,133,370 shares, equal to 10.0% of Journey Medical's common stock as of 03/31/2026. The filing lists sole dispositive power over all reported shares.

Does the Schedule 13G/A show voting control by Wasatch Advisors?

Yes. The filing discloses sole voting power for 1,979,366 shares, indicating Wasatch can direct votes for most of its economic position as reported on 03/31/2026.

Is the Wasatch Advisors filing an acquisition or a passive disclosure?

This is an amended Schedule 13G/A reporting beneficial ownership; it documents a holding rather than announcing an acquisition transaction. The filing does not state purchase timing or active trading plans.

Who signed the filing for Wasatch Advisors and when?

The amendment is signed by Mike Yeates, CEO of Wasatch Advisors, with signature date 04/06/2026, certifying the accuracy of the reported ownership information.





48115J109

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



Wasatch Advisors LP
Signature:Mike Yeates
Name/Title:CEO
Date:04/06/2026